BofA Securities Starts Neogenomics (NEO) at Buy

BofA Securities analyst Ivy Ma initiates coverage on Neogenomics (NASDAQ: NEO) with a Buy rating and a price target of $34.00.

• A one-stop shop for oncology testing
• Volume growth and share gains fueled by acquisitions

For an analyst ratings summary and ratings history on Neogenomics click here. For more ratings news on Neogenomics click here.

Shares of Neogenomics closed at $27.78 yesterday.

You May Also Be Interested In

• Correction: Citi Upgrades Sirius XM Radio (SIRI) to Neutral
• UBS Upgrades Swiss Prime Site AG (SPSN:SW) (SWPRF) to Buy
• Oppenheimer Reiterates Outperform Rating on Take-Two Interactive (TTWO)